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Figure 1. Use of statins for the prevention of cardiovascular events according to the 

































                                                 
1 The Popular Pharmacy Program is a partnership between the Brazilian Ministry of Health and the private 
pharmaceutical retail sector. In addition to the free-of-charge medicines for hypertension, diabetes and asthma, 
under WKH³6D~GHQmRWHPSUHoR´³+HDOWKLVSULFHOHVV´VWUDWHJ\WKHSURJUDPSURYLGHVstatins for dyslipidemia 














Figure 2. Sampling plan of the Brazilian Survey on Access, Use and Promotion of Rational 




NB: (a) Population estimated for 2014 by the Brazilian Institute of Geography and Statistics (IBGE). (b) 
P=0.50 is the ratio of elements to be estimated as it leads to greater sample size; z=1.96 is the normal curve 
value reduced to the 95% level of confidence; deff is the design effect, and d is the percentage sampling 
error. (c) Primary health care services were randomly selected from the National Registration of Health 
Establishments (CNES). (d) The average of GP appointments in the period spanned from July 2013 to May 



































































TABLE 1. Sociodemographic characteristics of statins users in the SUS primary health 
care. National Survey on Access, Use and Promotion of Rational Use of Medicines ± 
Services, 2015 
 






  na % (95% CI)  na % (95% CI)   
Sex         0.549 
Female 469 77.8 (71.3-83.1) 4,555 76.1 (74.3-77.8)  
Male 134 22.2 (16.9-28.7) 1,917 23.9 (22.2-25.7)  
Age (years)  
  
 <0.001 
18 - 44  54 9.6 (6.5-14.0) 2,817 45.6 (43.0-48.3)  
45 - 64  353 60.0 (52.7-66.9) 2,146 37.6 (35.7-39.5)  
 196 30.4 (25.3-36.0) 891 16.8 (14.9-18.8)  
Skin color/ethnicity    
 
 <0.001 
White 308 53.6 (45.5-61.5) 2,146 40.9 (37.2-44.6)  
Brown 253 41.0 (33.6-48.9) 3,163 49.8 (45.9-53.7)  
Black 39 5.2 (3.5-7.5) 517 7.8 (6.4-9.6)  
Yellow 1 0.2 (0.0-1.7) 46 1.3 (0.6-2.9)  
Indigenous 0 - 22 0.3 (0.1-0.6)  
Marital status  
  
 <0.001 
Single 68 8.4 (6.0-11.5) 1,406 20.3 (18.8-22.0)  
Married/common-law marriage b 376 68.2 (62.5-73.4) 3,640 65.1 (63.1-67.2)  
Others 159 23.5 (18.6-29.1) 862 14.5 (13.1-16.0)  
Education level  
  
 <0.001 
Illiterate 95 16.3 (11.2-23.3) 553 10.7 (8.7-13.1)  
Incomplete elementary  school 265 48.7 (41.7-55.7) 2,245 42.5 (39.1-46.0)  
Elementary school 80 12.0 (9.0-15.8) 755 12.7 (10.6-15.0)  
High school 130 17.8 (14.1-22.1) 1,923 28.2 (26.1-30.4)  
+LJKHUHGXFDWLRQ 33 5.2 (3.5-7.6) 432 6.0 (5.1-7.0)  
Economic class c  
  
 0.771 
A/B 97 16.0 (10.5-23.6) 975 15.0 (12.9-17.4)  
C 344 52.5 (46.1-58.8) 3,446 54.7 (51.5-57.9)  
D/E 161 31.5 (24.4-39.7) 1,484 30.2 (25.8-35.1)  
Country region       0.001 
North 40 1.4 (0.7-2.7) 1,046 5.4 (4.2-7.0)  
Northeast 105 25.6 (16.9-36.8) 1,112 29.4 (22.0-38.1)  
Midwest 69 3.3 (1.6-6.5) 1,031 5.8 (4.1-8.1)  
Southeast 136 32.2 (20.6-46.6) 1,282 33.6 (25.8-42.3)  
South 253 37.5 (25.4-51.4) 1,437 25.8 (19.3-33.6)  
Private health insurance (yes) 72 12.4 (8.1-18.5) 532 9.9 (7.2-13.4) 0.169 
NB: aUnweighted n-value; bAccording to Brazilian Law 10,406/2002, the common-law marriage between 
man and woman is defined as a family entity, configured in the public coexistence, continuous and lasting 
and established with the purpose of family formation. CAccording to the Brazilian Criteria 2015 and social 










Table 2. Lifestyle characteristics and indicators of health conditions of the statins users 
in SUS primary health care. National Survey on Access, Use and Promotion of Rational 
Use of Medicines ± Services, 2015 
 
  Current statin users   
Variables Yes (n=603) No (n=5,908) p-value 
  n
a % (95% CI) na % (95% CI)   
Alcohol consumption (yes) b 9 17.0 (13.0-22.0) 1,353 21.5 (19.2-24.0) 0.080 
Smoking (yes) 84 14.4 (10.8-19.0) 727 13.3 (11.9-14.9) 0.568 
Physical activity (yes) c 187 30.8 (25.1-37.1) 1,583 26.0 (22.7-29.6) 0.066 
Fat reduction diet (yes) 493 77.4 (72.8-81.4) 3,504 58.4 (55.1-61.5) <0.001 
Self-perception of health  
   0.006 
 Good/very good 253 40.3 (31.6-49.6) 3,178 53.0 (50.1-55.9)  
 Neither bad/nor good 279 48.1 (39.7-56.6) 2,193 38.0 (35.8-40.2)  
 Bad/very bad 70 11.6 (7.8-17.0) 528 9.1 (7.8-10.5)   
Number of chronic diseases 
 
   <0.001 
None 11 2.4 (1.0-5.3) 1,583 24.8 (22.6-27.2)  
One 70 12.8 (9.2-17.6) 1,592 28.8 (27.1-30.6)  
Two or more 492 84.9 (79.7-88.9) 2,481 46.4 (43.5-49.3)  
Chronic diseases 
 
    
- Diseases of the circulatory system 456 76.6 (71.4-81.1) 2,585 47.7 (44.7-50.8) <0.001 
Hypertension 439 73.0 (67.8-77.7) 2,500 45.9 (42.8-79.0)  
Heart diseases 153 24.1 (18.2-31.3) 444 8.1 (6.8-9.5)  
Stroke 35 4.7 (2.8-7.7) 165 2.9 (2.3-3.8)  
- Metabolic diseases 523 87.6 (83.4-90.9) 1,679 29.2 (26.9-31.6) <0.001 
Dyslipidemia 481 81.4 (76.5-85.4) 1,260 21.7 (19.7-23.8)  
Diabetes mellitus 234 36.6 (32.5-40.9) 843 15.1 (13.2-17.1)  
- Others 374 62.0 (54.9-68.7) 2,916 52.4 (49.0-55.7) 0.001 
Arthritis, arthrosis, or rheumatism 222 35.8 (30.3-41.8) 1,273 22.3 (19.8-25.0)  
Depression 166 25.8 (20.2-32.3) 1,176 21.7 (19.1-24.5)  
Chronic pulmonary disease 75 9.8 (6.9-13.6) 657 10.7 (9.3-12.2)  
Other diseases 152 26.0 (20.7-32.0) 1,227 21.5 (18.1-25.4)  
Number of drugs used 
    <0.001 
1 46 7.9 (5.5-11.1) 2,515 40.7 (37.6-44.0)  
2-4 319 55.1 (47.5-62.6) 3,021 52.6(50.0-55.1)  
SRO\SKDUPDF\ 238 37.0 (28.9-45.9) 372 6.7 (5.4-8.3)  
Emergency care (yes)d 147 21.8 (17.4-27.1) 1,643 25.2 (22.9-27.7) 0.164 
Hospitalization (yes)d 67 9.6 (6.5-13.9) 632 10.7 (9.1-12.5) 0.542 
NB: aUnweighted n-value; bAlcohol use were considered positive for report of more than once per month; 
cReport of physical activity or sports in the three months preceding the interview; dSelf-report referring to 













Table 3. Access, use and adherence to statins in the SUS primary health care services. National 
Survey on Access, Use and Promotion of Rational Use of Medicines ± Services, 2015 
 
Variable n a (603) % (95% CI ) 
Statin (ATC code) b   
Simvastatinc (C10AA01) 576 90.3 (84.2-94.2) 
Atorvastatin (C10AA05) 21 4.7 (1.7-12.4) 
Rosuvastatind (C10AA07) 11 1.9 (0.9-3.9) 
Pravastatin (C10AA03) 1 0.2 (0.0-1.4) 
Time using statin   
< 1 year 115 18.6 (14.9-22.9) 
\HDU 488 81.4 (77.1-85.1) 
< 1 year 115 18.6 (14.9-22.9) 
Access to statin   
SUS Pharmacy (free of charge) 387 68.1 (59.6-75.5) 
Private Pharmacy 111 16.7 (13.5-20.5) 
Popular Pharmacy c (co-payment) 95 13.8 (8.2-22.3) 
Other 10 1.5 (0.6-4.6) 
Self-reported of poor adherence e (yes) 41 6.5 (3.5-12.0) 
Causes of non-adherence   
Decision not to take the medicine 8 30.7 ( 18.6-46.1) 
Forgotten dose 9 24.1 (12.3-41.9) 
Lack of drug access f 15 23.5 (13.5-37.5) 
Adverse events 4 10.6 (2.9-31.7) 
Other 5 11.2 (4.6-24.7) 
NB: aUnweighted n value; bAccording to level five of the Anatomical Therapeutic Chemical (ATC) 
Classification Index (WHO, 2016); c Simvastatin is available in Popular Pharmacy Program network. The 
Ministry of Health fund up to 90% of the drugs price and the patient pays the difference between the 














































18 - 44 - - 
 
45 - 64 2.821 (1.614; 4.931) 
 




Illiterate/ Incomplete elementary school - - 
 
Elementary school 1.370 (0.974; 1.927) 
 
High school a 1.475 (1.022; 2.127) 
 
Higher education a 2.237 (1.246; 4.015) 
 
Region of residence 
  
0.003 
North - - 
 
Midwest 2.227 (1.073; 4.621) 
 
Southeast 2.533 (1.263; 5.078) 
 
Northeast 2.760 (1.414; 5.386) 
 
South 3.550 (1.843; 6.837) 
 
Metabolic diseases b 
  
<0.001 
No - - 
 





No - - 
 
Yes 1.570 (1.112; 2.218) 
 
Number of drugs used 
  
<0.001 
1 - - 
 
2-4 2.805 (1.844; 4.268) 
 




No - - 
 





No 1.866 (1.291; 2.697) 
 
Yes - - 
 
NB: p-value Hosmer-Lemeshow = 0.7197; a p-value= 0.038 for high school and p=0.007 for higher 
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